331 related articles for article (PubMed ID: 15001356)
1. Phage-peptide display identifies the interferon-responsive, death-activated protein kinase family as a novel modifier of MDM2 and p21WAF1.
Burch LR; Scott M; Pohler E; Meek D; Hupp T
J Mol Biol; 2004 Mar; 337(1):115-28. PubMed ID: 15001356
[TBL] [Abstract][Full Text] [Related]
2. Expansion of protein interaction maps by phage peptide display using MDM2 as a prototypical conformationally flexible target protein.
Burch L; Shimizu H; Smith A; Patterson C; Hupp TR
J Mol Biol; 2004 Mar; 337(1):129-45. PubMed ID: 15001357
[TBL] [Abstract][Full Text] [Related]
3. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
[TBL] [Abstract][Full Text] [Related]
4. p53 expression in CMV-infected cells: association with the alternative expression of the p53 transactivated genes p21/WAF1 and MDM2.
García JF; Piris MA; Lloret E; Orradre JL; Murillo PG; Martínez JC
Histopathology; 1997 Feb; 30(2):120-5. PubMed ID: 9067734
[TBL] [Abstract][Full Text] [Related]
5. The MDM2 ubiquitination signal in the DNA-binding domain of p53 forms a docking site for calcium calmodulin kinase superfamily members.
Craig AL; Chrystal JA; Fraser JA; Sphyris N; Lin Y; Harrison BJ; Scott MT; Dornreiter I; Hupp TR
Mol Cell Biol; 2007 May; 27(9):3542-55. PubMed ID: 17339337
[TBL] [Abstract][Full Text] [Related]
6. The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation.
Guerra B; Götz C; Wagner P; Montenarh M; Issinger OG
Oncogene; 1997 Jun; 14(22):2683-8. PubMed ID: 9178766
[TBL] [Abstract][Full Text] [Related]
7. HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage.
Pääjärvi G; Roudier E; Crisby M; Högberg J; Stenius U
FASEB J; 2005 Mar; 19(3):476-8. PubMed ID: 15625077
[TBL] [Abstract][Full Text] [Related]
8. Binding to the naturally occurring double p53 binding site of the Mdm2 promoter alleviates the requirement for p53 C-terminal activation.
Kaku S; Iwahashi Y; Kuraishi A; Albor A; Yamagishi T; Nakaike S; Kulesz-Martin M
Nucleic Acids Res; 2001 May; 29(9):1989-93. PubMed ID: 11328884
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B virus-X protein upregulates the expression of p21waf1/cip1 and prolongs G1-->S transition via a p53-independent pathway in human hepatoma cells.
Park US; Park SK; Lee YI; Park JG; Lee YI
Oncogene; 2000 Jul; 19(30):3384-94. PubMed ID: 10918595
[TBL] [Abstract][Full Text] [Related]
10. Novel targets of Akt, p21(Cipl/WAF1), and MDM2.
Zhou BP; Hung MC
Semin Oncol; 2002 Jun; 29(3 Suppl 11):62-70. PubMed ID: 12138399
[TBL] [Abstract][Full Text] [Related]
11. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease.
Sánchez-Beato M; Piris MA; Martínez-Montero JC; García JF; Villuendas R; García FJ; Orradre JL; Martínez P
J Pathol; 1996 Sep; 180(1):58-64. PubMed ID: 8943816
[TBL] [Abstract][Full Text] [Related]
12. Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance.
Kulikov R; Boehme KA; Blattner C
Mol Cell Biol; 2005 Aug; 25(16):7170-80. PubMed ID: 16055726
[TBL] [Abstract][Full Text] [Related]
13. The carboxy-terminal serine 392 phosphorylation site of human p53 is not required for wild-type activities.
Fiscella M; Zambrano N; Ullrich SJ; Unger T; Lin D; Cho B; Mercer WE; Anderson CW; Appella E
Oncogene; 1994 Nov; 9(11):3249-57. PubMed ID: 7936649
[TBL] [Abstract][Full Text] [Related]
14. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
[TBL] [Abstract][Full Text] [Related]
15. The contribution of the RING finger domain of MDM2 to cell cycle progression.
Argentini M; Barboule N; Wasylyk B
Oncogene; 2000 Aug; 19(34):3849-57. PubMed ID: 10951578
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
17. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage.
Maya R; Balass M; Kim ST; Shkedy D; Leal JF; Shifman O; Moas M; Buschmann T; Ronai Z; Shiloh Y; Kastan MB; Katzir E; Oren M
Genes Dev; 2001 May; 15(9):1067-77. PubMed ID: 11331603
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of p53, bcl-2, mdm2 and waf1/p21 proteins in colorectal adenocarcinomas.
Valassiadou KE; Stefanaki K; Tzardi M; Datseris G; Georgoulias V; Melissas J; Tsiftsis DD; Delides G; Kanavaros P
Anticancer Res; 1997; 17(4A):2571-6. PubMed ID: 9252682
[TBL] [Abstract][Full Text] [Related]
19. Dose-response transition from cell cycle arrest to apoptosis with selective degradation of Mdm2 and p21WAF1/CIP1 in response to the novel anticancer agent, aminoflavone (NSC 686,288).
Meng LH; Kohn KW; Pommier Y
Oncogene; 2007 Jul; 26(33):4806-16. PubMed ID: 17297446
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
